skip to search skip to navigation skip to main content

Archive: November 2016

Patients in Egypt can now benefit from a new first-in-class overactive bladder treatment

24th November 2016 in Product Launches

More than 500 million people around the world are affected by OAB[1] Around 40% of the OAB patients are silent sufferers and have never consulted a physician about their condition[2] Urinary dysfunction should not be considered as natural part of ageing  Astellas Pharma – World category leader in Urology- launches BETMIGA in Egypt  Cairo, Egypt;…

Read Full Post

Astellas Pharma launched its hormonal prostate cancer treatment in three-month dosing

10th November 2016 in Product Launches

More than 11% of the Iranian male population are within the risk age group for prostate cancer [1] Men in the Middle East region are approximately 3 times more likely to die from prostate cancer as compared with the Northern Europe [2] Early detection is more likely to increase the survival rate of prostate cancer…

Read Full Post

Prostate Cancer screening is vitally important for Jordan’s male population over 50

08th November 2016 in Product Launches

More than 8% of the Jordanian male population are within the risk age group for prostate cancer[1] Early detection may increase overall survival rate Currently men in Jordan are 5.3 times more likely to die from prostate cancer as compared with the USA[2] Astellas Pharma launched its prostate cancer treatment Xtandi™ providing effective disease treatment…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2018 Astellas Pharma